Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

Inclusion criteria: * Adults and children over 6 months old and bodyweight \> 5 kg * Able to be treated by oral route * Axillary temperature ≥ 37,5 C or history of fever during the previous 2 days * Symptomatic biologically confirmed Plasmodium vivax mono-infection, with parasitemia from 250 to 100000 parasites /µl of blood * Written informed consent of the patients and for children written informed consent of the parents/legal representative for children. Children able to understand the objectives and the risks of the study will sign an assent form. Exclusion criteria: * Known project of leaving the investigator site area during the follow-up period (42 days) * Hypersensitivity to one of the investigational medicinal products or to any of the excipients * Intake of an antimalarial treatment in the previous 30 days * History of hepatic and (or) haematological impairment during treatment with amodiaquine * Blurred vision suggesting a retinopathy * Presence of at least one danger sign of malaria * Pregnant or breast-feeding women * Women with childbearing potential not willing to use an effective contraceptive method(s) for the duration of the study * Known severe concomitant or underlying disease The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.